AR077757A1 - Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion - Google Patents
Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacionInfo
- Publication number
- AR077757A1 AR077757A1 ARP100102599A ARP100102599A AR077757A1 AR 077757 A1 AR077757 A1 AR 077757A1 AR P100102599 A ARP100102599 A AR P100102599A AR P100102599 A ARP100102599 A AR P100102599A AR 077757 A1 AR077757 A1 AR 077757A1
- Authority
- AR
- Argentina
- Prior art keywords
- rsv
- methods
- compositions
- sincicial
- respiratory
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones inmunogénicas que comprenden a la proteína RSV-F, métodos para preparar composiciones que contienen polipéptidos del ectodominio de la proteína RSV-F y determinadas proteínas y ácidos nucleicos RSV-F genéticamente modificados que codifican las proteínas RSV-F genéticamente modificadas. Las composiciones preparadas usando los métodos pueden contener polipéptidos del ectodominio de la proteína RSV-F en una forma y conformacion deseadas predominante o unica. También se describen métodos para inducir una respuesta inmune a la RSV- F.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22580509P | 2009-07-15 | 2009-07-15 | |
US29442610P | 2010-01-12 | 2010-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR077757A1 true AR077757A1 (es) | 2011-09-21 |
Family
ID=42834367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100102599A AR077757A1 (es) | 2009-07-15 | 2010-07-15 | Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion |
Country Status (22)
Country | Link |
---|---|
US (13) | US20120164176A1 (es) |
EP (6) | EP2453918B1 (es) |
JP (2) | JP5829210B2 (es) |
CN (2) | CN102639147B (es) |
AR (1) | AR077757A1 (es) |
BR (1) | BR112012001666A2 (es) |
CA (1) | CA2768186A1 (es) |
CL (1) | CL2012000119A1 (es) |
CO (1) | CO6491045A2 (es) |
DK (1) | DK3178490T3 (es) |
ES (2) | ES2563730T3 (es) |
HR (1) | HRP20220756T1 (es) |
HU (1) | HUE058971T2 (es) |
LT (1) | LT3178490T (es) |
MX (1) | MX2012000667A (es) |
PL (1) | PL3178490T3 (es) |
PT (1) | PT3178490T (es) |
RU (1) | RU2585227C2 (es) |
SG (1) | SG178026A1 (es) |
SI (1) | SI3178490T1 (es) |
TW (1) | TW201116294A (es) |
WO (1) | WO2011008974A2 (es) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
EP3718566B1 (en) | 2008-12-09 | 2024-06-12 | Novavax, Inc. | Modified rsv f proteins and methods of their use |
DK3178490T3 (da) | 2009-07-15 | 2022-06-20 | Glaxosmithkline Biologicals Sa | RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse |
SI3243526T1 (sl) | 2010-07-06 | 2020-02-28 | Glaxosmithkline Biologicals S.A. | Dostava RNA za sprožitev večih imunskih poti |
EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
BR112013000244A2 (pt) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipossomas com lipídeos apresentando pka vantajoso para administração de rna |
SI4005592T1 (sl) | 2010-07-06 | 2023-03-31 | Glaxosmithkline Biologicals S.A. | Virionom podobni dostavni delci za samopodvojene molekule RNA |
ES2938866T3 (es) | 2010-08-31 | 2023-04-17 | Glaxosmithkline Biologicals Sa | Liposomas pegilados para la administración de ARN que codifica para inmunógeno |
AU2011296062A1 (en) | 2010-08-31 | 2013-04-04 | Novartis Ag | Small liposomes for delivery of immunogen-encoding RNA |
ES2716243T3 (es) | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Plataformas de suministro de antígenos |
EP3527224A1 (en) | 2011-01-26 | 2019-08-21 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
WO2012117045A1 (en) * | 2011-03-02 | 2012-09-07 | Intervet International B.V. | Infectious bronchitis virus (ibv) spike protein as subunit vaccine |
CA2830901A1 (en) * | 2011-03-22 | 2012-09-27 | Mucosis B.V. | Immunogenic compositions in particulate form and methods for producing the same |
WO2012129483A1 (en) * | 2011-03-24 | 2012-09-27 | Novartis Ag | Adjuvant nanoemulsions with phospholipids |
PT2707385T (pt) * | 2011-05-13 | 2017-12-19 | Glaxosmithkline Biologicals Sa | Antigénios de f de rsv pré-fusão |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
SG10201605537XA (en) | 2011-07-06 | 2016-09-29 | Novartis Ag | Liposomes having useful n:p ratio for delivery of rna molecules |
EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
DK2750707T3 (en) * | 2011-08-31 | 2019-02-11 | Glaxosmithkline Biologicals Sa | PEGYLED LIPOSOMES FOR DELIVERING IMMUNOGEN-CODING RNA |
US9125870B2 (en) * | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
CN104619719A (zh) * | 2012-04-10 | 2015-05-13 | 宾夕法尼亚大学理事会 | 人呼吸道合胞病毒共有抗原、由其制备的核酸构建体和疫苗及其使用方法 |
EP3656396A1 (en) | 2012-08-01 | 2020-05-27 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine |
CA2879939A1 (en) | 2012-08-06 | 2014-02-13 | Glaxosmithkline Biologicals S.A. | Novel method |
US20140037680A1 (en) * | 2012-08-06 | 2014-02-06 | Glaxosmithkline Biologicals, S.A. | Novel method |
JP2016501196A (ja) | 2012-11-20 | 2016-01-18 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Rsvf融合前三量体 |
WO2014108515A1 (en) * | 2013-01-10 | 2014-07-17 | Novartis Ag | Influenza virus immunogenic compositions and uses thereof |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
EP2970398B1 (en) | 2013-03-13 | 2024-05-08 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Prefusion rsv f proteins and their use |
US9060975B2 (en) * | 2013-03-14 | 2015-06-23 | Mucosis Bv | Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions |
CN105189756B (zh) | 2013-03-14 | 2021-06-11 | 爱默蕾大学 | 具有沉默突变的重组rsv、其相关疫苗和方法 |
TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法 |
DE102013004595A1 (de) * | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
JP2016516755A (ja) * | 2013-04-08 | 2016-06-09 | メディミューン,エルエルシー | ワクチン組成物及びその使用方法 |
MX361774B (es) * | 2013-04-25 | 2018-12-17 | Janssen Vaccines & Prevention Bv | Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados. |
PE20160045A1 (es) | 2013-06-17 | 2016-02-18 | Crucell Holland Bv | Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados |
WO2015013551A1 (en) | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
KR20160040290A (ko) | 2013-08-05 | 2016-04-12 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 조합 면역원성 조성물 |
AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
EP2974739A1 (en) | 2014-07-15 | 2016-01-20 | Novartis AG | RSVF trimerization domains |
JP6664338B2 (ja) | 2014-06-13 | 2020-03-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組合せ物 |
WO2016149417A1 (en) * | 2015-03-17 | 2016-09-22 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
WO2017005844A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
JP6840718B2 (ja) | 2015-07-07 | 2021-03-10 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | 安定化された可溶性融合前rsv fポリペプチド |
US11324816B2 (en) * | 2015-08-31 | 2022-05-10 | Technovax, Inc. | Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine |
US10426829B2 (en) | 2015-09-03 | 2019-10-01 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
PE20181354A1 (es) | 2015-12-23 | 2018-08-22 | Pfizer | Mutantes de proteina f de rsv |
CN115960263A (zh) | 2016-03-29 | 2023-04-14 | 美国政府(由卫生和人类服务部的部长所代表) | 取代修饰的融合前rsv f蛋白及其用途 |
BR112018070323A2 (pt) | 2016-04-05 | 2019-01-29 | Janssen Vaccines & Prevention Bv | vacina contra rsv |
AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
CN106124767A (zh) * | 2016-05-12 | 2016-11-16 | 广州瑞辉生物科技股份有限公司 | 呼吸道合胞病毒IgA抗体检测试纸条及其检测方法 |
WO2017207480A1 (en) | 2016-05-30 | 2017-12-07 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion rsv f proteins |
TWI634899B (zh) * | 2016-11-22 | 2018-09-11 | 國立臺灣大學 | 包含類b肝病毒顆粒作為佐劑的疫苗組成物 |
GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
EP3624844A1 (en) | 2017-05-17 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
IE87414B1 (en) | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
JP7317796B2 (ja) | 2017-07-24 | 2023-07-31 | ノババックス,インコーポレイテッド | 呼吸器疾患を治療するための方法および組成物 |
CN111163799A (zh) * | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | 用于异源repRNA免疫接种的方法和组合物 |
US11267848B2 (en) | 2017-08-07 | 2022-03-08 | Calder Biosciences Inc. | Conformationally stabilized RSV pre-fusion F proteins |
CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
EP3681533A1 (en) | 2017-09-15 | 2020-07-22 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
BR112020010790A2 (pt) | 2017-12-01 | 2020-11-10 | Glaxosmithkline Biologicals S.A. | purificação da saponina |
JP2021511356A (ja) | 2018-01-29 | 2021-05-06 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 安定化rsv fタンパク質およびその使用 |
KR20210004959A (ko) | 2018-03-19 | 2021-01-13 | 노바백스, 인코포레이티드 | 다가 인플루엔자 나노입자 백신 |
US11576960B2 (en) * | 2018-03-30 | 2023-02-14 | Georgia State University Research Foundation, Inc. | Respiratory syncytial virus (RSV) vaccines |
WO2020030572A1 (en) | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
KR20200050264A (ko) * | 2018-11-01 | 2020-05-11 | 에스케이바이오사이언스(주) | 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물 |
CN109694400A (zh) * | 2019-01-31 | 2019-04-30 | 苏州高泓利康生物科技有限公司 | 一种表达呼吸道合胞病毒f蛋白及其制备方法 |
JP2022535091A (ja) | 2019-06-05 | 2022-08-04 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
JP2023509666A (ja) * | 2019-12-31 | 2023-03-09 | シァメン・ユニヴァーシティ | 分子の細胞内送達用の多量体化送達システム |
EP4130047A1 (en) * | 2020-02-27 | 2023-02-08 | Huahui Health Ltd. | Soluble ace2 and fusion protein, and applications thereof |
WO2021249009A1 (en) * | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Rsv vaccine compositions, methods, and uses thereof |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
CN114685676B (zh) * | 2020-12-28 | 2024-02-13 | 兰州生物制品研究所有限责任公司 | 一种重组蛋白及其表达方法、纯化方法及用途 |
EP4169513A1 (en) | 2021-10-19 | 2023-04-26 | GlaxoSmithKline Biologicals S.A. | Adjuvant composition comprising sting agonists |
WO2023237649A1 (en) * | 2022-06-10 | 2023-12-14 | Glaxosmithkline Biologicals Sa | Rsv vaccination with trimeric rsv f fusion protein |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
WO2024078597A1 (en) * | 2022-10-13 | 2024-04-18 | Rvac Medicines (Us) , Inc. | Rsv f protein variants and uses thereof |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
CN116284266B (zh) * | 2022-11-21 | 2024-01-19 | 怡道生物科技(苏州)有限公司 | 突变型呼吸道合胞病毒融合前f蛋白及其应用 |
WO2024127181A1 (en) | 2022-12-11 | 2024-06-20 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
CN117304278B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
CN117304280B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
Family Cites Families (175)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US118A (en) | 1837-02-10 | Improvement in the machine for weighing heavy bodies | ||
US139A (en) | 1837-03-11 | Robert wilson | ||
US119A (en) | 1837-02-10 | Improvement in the machine for weighing heavy bodies | ||
US4186745A (en) | 1976-07-30 | 1980-02-05 | Kauzlarich James J | Porous catheters |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4707543A (en) | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US5149650A (en) | 1986-01-14 | 1992-09-22 | University Of North Carolina At Chapel Hill | Vaccines for human respiratory virus |
US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5726292A (en) | 1987-06-23 | 1998-03-10 | Lowell; George H. | Immuno-potentiating systems for preparation of immunogenic materials |
US5639853A (en) | 1987-09-29 | 1997-06-17 | Praxis Biologics, Inc. | Respiratory syncytial virus vaccines |
JP2716503B2 (ja) | 1987-12-23 | 1998-02-18 | ジ・アップジョン・カンパニー | ヒト呼吸系シンシチウムウイルスの糖蛋白類の免疫原性セグメントを含有するキメラ糖蛋白類 |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
AU627226B2 (en) | 1988-08-25 | 1992-08-20 | Liposome Company, Inc., The | Influenza vaccine and novel adjuvants |
US5238944A (en) | 1988-12-15 | 1993-08-24 | Riker Laboratories, Inc. | Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine |
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
DK0452457T3 (da) | 1989-11-03 | 1998-03-02 | Univ Vanderbilt | Fremgangsmåde til in vivo fjernelse af funktionelle fremmede gener |
US5674192A (en) | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
SG70625A1 (en) | 1991-03-01 | 2000-02-22 | Minnesota Mining & Mfg | 1-Substituted 2-substituted 1H-imidazo(4, 5-c) quinolin-4-amines |
US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
US5266575A (en) | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
IL105325A (en) | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US5340740A (en) | 1992-05-15 | 1994-08-23 | North Carolina State University | Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
ATE188613T1 (de) | 1992-06-25 | 2000-01-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
KR960700271A (ko) | 1993-01-08 | 1996-01-19 | 로렌스 티. 웰츠 | 인간 호흡계 합포체 바이러스 fg 당단백질의 정제 및 리폴딩 방법(process for the purification and refolding of human respiratory syncytial virus fg glycoprotein) |
US5395937A (en) | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
HU219056B (hu) | 1993-03-23 | 2001-02-28 | Smithkline Beecham Biologicals Sa | 3-O-Dezacilezett monofoszforil-lipid A-t tartalmazó vakcinakészítmény |
US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
AU681687B2 (en) | 1993-07-15 | 1997-09-04 | Minnesota Mining And Manufacturing Company | Imidazo(4,5-c)pyridin-4-amines |
AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
US5961970A (en) | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
DK0729473T3 (da) | 1993-11-17 | 2000-10-30 | Deutsche Om Arzneimittel Gmbh | Glucosamin-disaccharider, fremgangsmåde til deres fremstilling farmaceutisk sammensætning deraf og deres anvendelse |
US5397307A (en) | 1993-12-07 | 1995-03-14 | Schneider (Usa) Inc. | Drug delivery PTCA catheter and method for drug delivery |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
JP3403233B2 (ja) | 1994-01-20 | 2003-05-06 | テルモ株式会社 | バルーンカテーテル |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
FR2718452B1 (fr) | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ATE420171T1 (de) | 1994-07-15 | 2009-01-15 | Univ Iowa Res Found | Immunomodulatorische oligonukleotide |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
FR2726003B1 (fr) | 1994-10-21 | 2002-10-18 | Agronomique Inst Nat Rech | Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires |
WO1996015811A1 (en) | 1994-11-17 | 1996-05-30 | Imperial College Of Science, Technology & Medicine | Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
GB9503863D0 (en) | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US5666153A (en) | 1995-10-03 | 1997-09-09 | Virtual Shopping, Inc. | Retractable teleconferencing apparatus |
US6020182A (en) * | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
US6764840B2 (en) | 1997-05-08 | 2004-07-20 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6303347B1 (en) | 1997-05-08 | 2001-10-16 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
US6090619A (en) | 1997-09-08 | 2000-07-18 | University Of Florida | Materials and methods for intracellular delivery of biologically active molecules |
ES2236946T3 (es) | 1997-09-19 | 2005-07-16 | Wyeth Holdings Corporation | Peptidos derivados de la proteina de union (g) del virus respiratorio sincitial. |
WO1999016500A2 (en) | 1997-10-01 | 1999-04-08 | Medtronic Ave, Inc. | Drug delivery and gene therapy delivery system |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
PL354714A1 (en) | 1998-04-09 | 2004-02-09 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
EP1089913A1 (fr) | 1998-06-08 | 2001-04-11 | SCA Emballage France | Emballage a remise a plat rapide |
AU761396B2 (en) | 1998-06-30 | 2003-06-05 | Om Pharma | Novel acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
DE69935606T9 (de) | 1998-10-16 | 2021-03-11 | Glaxosmithkline Biologicals S.A. | Adjuvanzsysteme und impfstoffe |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
CA2361421A1 (en) | 1999-02-03 | 2000-08-10 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
DE60012711T2 (de) | 1999-03-26 | 2005-08-18 | Vical, Inc., San Diego | Adjuvanszusammensetzungen zur erhöhung der immunantwort auf polynukleotid-basierende impfstoffe |
US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
EP1221971A2 (en) | 1999-09-24 | 2002-07-17 | SmithKline Beecham Biologics SA | Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
JP2003509452A (ja) | 1999-09-24 | 2003-03-11 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ポリオキシエチレンアルキルエーテル又はエステル及び少なくとも一つのノニオン界面活性剤を含有するアジュバント |
DE60022665T2 (de) | 1999-09-25 | 2006-06-22 | Coley Pharmaceutical Gmbh | Immunstimulierende nukeinsäuren |
AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
EP1311288A1 (en) | 2000-01-20 | 2003-05-21 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
AU2001293233A1 (en) | 2000-09-01 | 2002-03-13 | Chiron Corporation | Aza heterocyclic derivatives and their therapeutic use |
EP1650203B1 (en) | 2000-09-11 | 2008-02-20 | Novartis Vaccines and Diagnostics, Inc. | Process of preparation of benzimidazol-2-yl quinolinone derivatives |
ES2298269T3 (es) | 2000-09-26 | 2008-05-16 | Idera Pharmaceuticals, Inc. | Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales. |
WO2002042326A1 (en) | 2000-11-22 | 2002-05-30 | Biota Scientific Management Pty Ltd | A method of expression and agents identified thereby |
US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
US6677348B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Aryl ether substituted imidazoquinolines |
US6667312B2 (en) | 2000-12-08 | 2003-12-23 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
UA74852C2 (en) | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
US6677347B2 (en) | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
US6664265B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Amido ether substituted imidazoquinolines |
SG141239A1 (en) | 2001-01-26 | 2008-04-28 | Selexis Sa | Matrix attachment regions and methods for use thereof |
EP1372706B1 (en) | 2001-03-09 | 2010-12-01 | ID Biomedical Corporation of Quebec | Proteosome-liposaccharide vaccine adjuvant |
CN1250548C (zh) | 2001-04-17 | 2006-04-12 | 大日本住友制药株式会社 | 新的腺嘌呤衍生物 |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
JP2005513021A (ja) | 2001-11-16 | 2005-05-12 | スリーエム イノベイティブ プロパティズ カンパニー | Irm化合物およびトール様受容体経路に関する方法および組成物 |
FR2832423B1 (fr) | 2001-11-22 | 2004-10-08 | Vivalis | Systeme d'expression de proteines exogenes dans un systeme aviaire |
US7321033B2 (en) | 2001-11-27 | 2008-01-22 | Anadys Pharmaceuticals, Inc. | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof |
DE60234376D1 (de) | 2001-11-27 | 2009-12-24 | Anadys Pharmaceuticals Inc | 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimin-nucleoside und ihre verwendung |
US6677349B1 (en) | 2001-12-21 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
JP4553588B2 (ja) | 2002-02-21 | 2010-09-29 | メディミューン,エルエルシー | メタニューモウイルス(metapneumovirus)株と、ワクチン製剤でのおよび抗原配列発現用ベクターとしてのその使用 |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
US7071216B2 (en) | 2002-03-29 | 2006-07-04 | Chiron Corporation | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
WO2003083095A1 (en) * | 2002-04-03 | 2003-10-09 | Akzo Nobel N.V. | Viral mutants, manipulated in the furin cleavage sites of glycoproteins |
EP1511746A2 (en) | 2002-05-29 | 2005-03-09 | 3M Innovative Properties Company | Process for imidazo[4,5-c]pyridin-4-amines |
EP1551228B1 (en) | 2002-06-13 | 2012-10-03 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
CA2496246A1 (en) | 2002-08-23 | 2004-03-04 | Chiron Corporation | Pyrrole based inhibitors of glycogen synthase kinase 3 |
ATE471335T1 (de) | 2002-12-23 | 2010-07-15 | Vical Inc | Impfstoffe gegen infektionen mit dem humanen zytomegalivirus auf grundlage von codonoptimierten polynukleotiden |
EP1587473A4 (en) | 2002-12-27 | 2008-08-13 | Novartis Vaccines & Diagnostic | THIOSEMICARBAZONES ANTIVIRAL AND IMMUNOSTIMULANTS |
US8193185B2 (en) | 2003-01-21 | 2012-06-05 | Novartis Vaccines And Diagnostics, Inc. | Use of tryptanthrin compounds for immune potentiation |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8 |
CA2520124A1 (en) | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of benzazole compounds for immunopotentiation |
US7368537B2 (en) | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
JP5396653B2 (ja) | 2003-10-24 | 2014-01-22 | セレキス エスアー | Mar配列の多トランスフェクション手順による高効率の遺伝子導入および哺乳動物細胞における発現 |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
CN1964626A (zh) | 2004-03-31 | 2007-05-16 | 纽约大学 | 新型合成c-糖脂、其合成及其治疗传染病、癌症和自身免疫性疾病的用途 |
KR20070008625A (ko) | 2004-04-05 | 2007-01-17 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
WO2005116270A2 (en) | 2004-05-18 | 2005-12-08 | Vical Incorporated | Influenza virus vaccine composition and method of use |
WO2006002422A2 (en) | 2004-06-24 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Compounds for immunopotentiation |
FR2873378A1 (fr) | 2004-07-23 | 2006-01-27 | Pierre Fabre Medicament Sa | Complexes immunogenes, leur procede de preparation et leur utilisation dans des compositions pharmaceutiques |
CN101014618B (zh) | 2004-07-23 | 2013-01-02 | 诺华疫苗和诊断有限公司 | 抗原的寡聚装配多肽 |
DK3312272T3 (da) | 2004-10-08 | 2019-12-02 | Us Gov Health & Human Services | Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner |
GB0422439D0 (en) | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
US20080233150A1 (en) | 2006-11-16 | 2008-09-25 | Gale Smith | Respiratory syncytial virus-virus like particle (vlps) |
JP2010522540A (ja) * | 2007-03-21 | 2010-07-08 | アイディー バイオメディカル コーポレイション オブ ケベック | キメラ抗原 |
EP2164860A2 (en) | 2007-06-06 | 2010-03-24 | Nationwide Children's Hospital, Inc. | Methods and compositions relating to viral fusion proteins |
CN101148479A (zh) * | 2007-09-11 | 2008-03-26 | 浙江理工大学 | 一种重组类人胶原蛋白及生物合成方法 |
AU2008340949A1 (en) | 2007-12-24 | 2009-07-02 | Glaxosmithkline Biologicals S.A. | Recombinant RSV antigens |
US8466167B2 (en) | 2008-03-03 | 2013-06-18 | Irm Llc | Compounds and compositions as TLR activity modulators |
ES2594102T3 (es) | 2008-04-18 | 2016-12-15 | Vaxinnate Corporation | Mutantes por deleción de la flagelina y métodos para su uso |
WO2009132206A1 (en) | 2008-04-25 | 2009-10-29 | Liquidia Technologies, Inc. | Compositions and methods for intracellular delivery and release of cargo |
EP2313085A2 (en) * | 2008-07-15 | 2011-04-27 | Novartis AG | Immunogenic amphipathic peptide compositions |
KR20110045008A (ko) | 2008-07-18 | 2011-05-03 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원 |
EP3718566B1 (en) * | 2008-12-09 | 2024-06-12 | Novavax, Inc. | Modified rsv f proteins and methods of their use |
WO2010077712A1 (en) | 2008-12-09 | 2010-07-08 | Novavax, Inc. | Bovine respiratory syncytial virus virus-like particle (vlps) |
US9492531B2 (en) | 2009-06-24 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Recombinant RSV vaccines |
MX2012000036A (es) | 2009-06-24 | 2012-02-28 | Glaxosmithkline Biolog Sa | Vacuna. |
DK3178490T3 (da) | 2009-07-15 | 2022-06-20 | Glaxosmithkline Biologicals Sa | RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
CA2830901A1 (en) | 2011-03-22 | 2012-09-27 | Mucosis B.V. | Immunogenic compositions in particulate form and methods for producing the same |
PT2707385T (pt) | 2011-05-13 | 2017-12-19 | Glaxosmithkline Biologicals Sa | Antigénios de f de rsv pré-fusão |
ES2395677B1 (es) | 2011-07-29 | 2013-12-26 | Instituto De Salud Carlos Iii | Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma. |
ES2900331T3 (es) | 2014-10-15 | 2022-03-16 | Amgen Inc | Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas |
MX2019011599A (es) | 2017-03-30 | 2019-12-19 | Univ Queensland | Moleculas quimericas y usos de las mismas. |
-
2010
- 2010-07-15 DK DK16190004.8T patent/DK3178490T3/da active
- 2010-07-15 CN CN201080040594.9A patent/CN102639147B/zh not_active Expired - Fee Related
- 2010-07-15 HU HUE16190004A patent/HUE058971T2/hu unknown
- 2010-07-15 SG SG2012002481A patent/SG178026A1/en unknown
- 2010-07-15 US US13/383,897 patent/US20120164176A1/en not_active Abandoned
- 2010-07-15 SI SI201032111T patent/SI3178490T1/sl unknown
- 2010-07-15 AR ARP100102599A patent/AR077757A1/es unknown
- 2010-07-15 BR BR112012001666A patent/BR112012001666A2/pt not_active IP Right Cessation
- 2010-07-15 ES ES10734875.7T patent/ES2563730T3/es active Active
- 2010-07-15 TW TW099123300A patent/TW201116294A/zh unknown
- 2010-07-15 PL PL16190004.8T patent/PL3178490T3/pl unknown
- 2010-07-15 EP EP10734875.7A patent/EP2453918B1/en active Active
- 2010-07-15 RU RU2012105308/10A patent/RU2585227C2/ru not_active IP Right Cessation
- 2010-07-15 EP EP22214601.1A patent/EP4218799A1/en active Pending
- 2010-07-15 HR HRP20220756TT patent/HRP20220756T1/hr unknown
- 2010-07-15 LT LTEP16190004.8T patent/LT3178490T/lt unknown
- 2010-07-15 PT PT161900048T patent/PT3178490T/pt unknown
- 2010-07-15 EP EP16190004.8A patent/EP3178490B1/en active Active
- 2010-07-15 EP EP21199223.5A patent/EP3988115A3/en active Pending
- 2010-07-15 WO PCT/US2010/042161 patent/WO2011008974A2/en active Application Filing
- 2010-07-15 CN CN201510703646.0A patent/CN105214080A/zh active Pending
- 2010-07-15 JP JP2012520789A patent/JP5829210B2/ja not_active Expired - Fee Related
- 2010-07-15 ES ES16190004T patent/ES2918381T3/es active Active
- 2010-07-15 EP EP22214608.6A patent/EP4218800A1/en active Pending
- 2010-07-15 US US12/836,931 patent/US20110305727A1/en not_active Abandoned
- 2010-07-15 CA CA2768186A patent/CA2768186A1/en not_active Abandoned
- 2010-07-15 EP EP22200670.2A patent/EP4183412A1/en active Pending
- 2010-07-15 MX MX2012000667A patent/MX2012000667A/es active IP Right Grant
-
2012
- 2012-01-13 CL CL2012000119A patent/CL2012000119A1/es unknown
- 2012-01-17 CO CO12006115A patent/CO6491045A2/es unknown
-
2015
- 2015-05-08 JP JP2015095502A patent/JP2015145422A/ja active Pending
-
2017
- 2017-08-16 US US15/678,798 patent/US11261239B2/en active Active
-
2021
- 2021-12-29 US US17/564,962 patent/US11820812B2/en active Active
-
2022
- 2022-06-23 US US17/848,176 patent/US11629181B2/en active Active
- 2022-06-23 US US17/848,205 patent/US11655284B2/en active Active
-
2023
- 2023-02-22 US US18/173,006 patent/US11827694B2/en active Active
- 2023-05-24 US US18/323,185 patent/US20230357370A1/en active Pending
- 2023-05-24 US US18/323,209 patent/US20230348575A1/en active Pending
- 2023-05-24 US US18/323,166 patent/US20240034773A1/en active Pending
- 2023-05-24 US US18/323,192 patent/US20230357371A1/en active Pending
- 2023-05-24 US US18/323,215 patent/US20230303669A1/en active Pending
- 2023-05-24 US US18/323,177 patent/US20230357369A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR077757A1 (es) | Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion | |
CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
MX2012000036A (es) | Vacuna. | |
WO2008148104A8 (en) | Novel vlps derived from cells that do not express a viral matrix or core protein | |
PE20140986A1 (es) | Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae | |
WO2014018858A3 (en) | Multimeric fusion protein vaccine and immunotherapeutic | |
WO2009073330A3 (en) | Novel vaccines against multiple subtypes of influenza virus | |
WO2007048089A3 (en) | Multi-plasmid system for the production of influenza virus | |
BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
CL2013003634A1 (es) | Complejo que comprende una proteina de fusion que comprende, un peptido viral, peptido conector, microglobulina beta 2 , peptido conector, dominios extracelulares alfa 1, 2 y 3 de mhc de clase i y un tercer peptido conector; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso | |
AR059772A1 (es) | Composiciones que incuyen hemaglutinina metodos de elaboracion y metodos de uso de las mismas | |
BRPI0922867B8 (pt) | glicoproteina de fusão (f) de vírus sincicial respiratório (rsv), ácido nucleico isolado, célula hospedeira, composição de vacina e micela purificada | |
WO2009076778A8 (en) | Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin | |
BR112013003522A8 (pt) | "polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, uso, método de preparação, bem como ácido nucleico codificando os mesmos" | |
IN2014DN05695A (es) | ||
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
BR112015002131A8 (pt) | Vírus vaccinia ankara modificado (mva) recombinante, composição farmacêutica e uso do referido mva recombinante | |
AR061894A1 (es) | Vacunas para malaria | |
WO2012047679A3 (en) | Consensus antigen constructs and vaccines made there form, and methods of using same to treat malaria | |
WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
IN2014DN05805A (es) | ||
WO2005115448A8 (en) | Multi plasmid system for the production of influenza virus | |
WO2008103819A3 (en) | Chimeric newcastle disease virus vlps | |
CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |